3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Unknown
1
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
64
Colorectal Neoplasms
58
Rectal Neoplasms
46
Stomach Neoplasms
44
Neoplasm Metastasis
16
Pancreatic Neoplasms
15
Colonic Neoplasms
13
Triple Negative Breast Neoplasms
11
Neoplasms
11
Esophageal Neoplasms
9
Nasopharyngeal Carcinoma
8
Locally Advanced Rectal Cancer
7
Esophageal Squamous Cell Carcinoma
7
Cholangiocarcinoma
6
Biliary Tract Neoplasms
6
Carcinoma, Hepatocellular
5
HER2 Positive Metastatic Breast Cancer
4
Colorectal Cancer Metastatic
4
Adenocarcinoma
4
Solid Tumor
3
Recurrence
3
Gallbladder Neoplasms
3
Anus Neoplasms
3
Advanced Breast Cancer
3
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumors
2
Neuroendocrine Tumors
2
Locally Advanced Colon Cancer
2
Hyperthermia
2
Head and Neck Neoplasms
2
Interventions
Doxorubicin
19
Radiotherapy
10
Ifosfamide
10
apatinib
9
anlotinib
8
Cyclophosphamide
8
camrelizumab
7
Vincristine
5
Dactinomycin
5
toripalimab
3
Trabectedin
3
Radiation Dose Hypofractionation
3
Ipilimumab
3
Gemcitabine
3
Etoposide
3
Docetaxel
3
selinexor
2
ribociclib
2
envafolimab
2
brostallicin
2
Topotecan
2
Thalidomide
2
Temozolomide
2
Sorafenib
2
Oncolytic Virotherapy
2
Nivolumab
2
Neoadjuvant Therapy
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Sarcoma
×
Capecitabine
×
Clear all
NCT03775525
2022-12-23
GEN602
Genzada Pharmaceuticals USA, Inc.
Phase 1
Unknown
127 enrolled